SCHEMBL186665

SCHEMBL186665

O=C(O)C1CNC(CS)C(=O)N1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CAD P27708 1/20 0.46
MME P08473 14/20 0.39
ACE P12821 9/20 0.38
ECE1 P42892 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186846 0.85 CAD (0.35) CAD
SCHEMBL186701 0.84 ITGB3 (0.40) CAD
SCHEMBL186487 0.81 ITGB3 (0.38) CAD
SCHEMBL186077 0.81 NPSR1 (0.40) CAD
SCHEMBL28779150 0.80 CAD (0.33) CADMMEACE
SCHEMBL186542 0.80 ITGB3 (0.36)
SCHEMBL10186994 0.78 ALDH1A1 (0.42)
SCHEMBL185633 0.78 GAA (0.40)
SCHEMBL186888 0.77 HDAC8 (0.51)
SCHEMBL186628 0.77 HDAC8 (0.49) CAD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101484171-B Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES INC 2015-05-06 CN disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2009-03-12 US disclosed
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2009-03-12 US disclosed
EP-2004352-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 CAD 3346/4885MME 695/4885ACE 2587/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR CAD 3526/4885MME 1152/4885ACE 2064/4885
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics MC1R, MC3R, MC5R CAD 4418/4885MME 938/4885ACE 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.